Skip to main content

Table 2 Dynamics of MHC-I and MHC-II molecules in spleen lymphocytes

From: Protective immunity against acute toxoplasmosis in BALB/c mice induced by a DNA vaccine encoding Toxoplasma gondii elongation factor 1-alpha

Marker (%)

Time point

Groups (n = 5)

Blank

PBS

PVAXI

PVAX-EF-1a

MHC-I

Week 0

18.19 ± 2.46

17.17 ± 2.62

16.99 ± 1.38

17.29 ± 2.34

 

Week 2

16.55 ± 2.15

17.13 ± 1.91

17.06 ± 2.44

24.23 ± 3.33a

 

Week 4

17.64 ± 1.82

18.02 ± 1.91

17.62 ± 1.46

31.44 ± 3.54a

 

Week 6

17.88 ± 1.78

17.76 ± 1.16

18.14 ± 2.30

32.96 ± 3.04a

MHC-II

Week 0

3.07 ± 0.97

2.88 ± 0.37

3.31 ± 0.49

3.27 ± 0.61

 

Week 2

2.99 ± 0.71

3.17 ± 0.38

3.07 ± 0.97

4.84 ± 1.86a

 

Week 4

3.25 ± 0.45

3.17 ± 0.38

3.27 ± 0.59

7.52 ± 1.42a

 

Week 6

3.22 ± 0.56

3.11 ± 0.73

3.24 ± 0.53

8.26 ± 1.23a

  1. Data are presented as the mean ± SD (n = 5). a represents statistically highly significant difference (p < 0.01) as compared with control groups: Blank, PBS and pVAXI